ArriVent BioPharma, Inc.
AVBP- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- SEC CIK
- 0001868279
No open-market purchases or sales by ArriVent BioPharma, Inc. insiders were filed in the last 90 days; 157 institutions reported holding it in 13F filings for Q2 2026, worth $1.60B in total; HHLR Advisors (Hillhouse) is the only superinvestor holding it.
Key figures
- Insider buysOpen market, last 90 days
- 0
- Insider sellsOpen market, last 90 days
- 0
- 13F holdersQ2 2026, +20 vs. previous quarter
- 157
- 13F valueReported value at the end of Q2 2026
- $1.60B
- Superinvestors holdingAt the end of Q2 2026
- 1
Price chart
Superinvestors holding AVBP, Q2 2026
1 superinvestor reports holding ArriVent BioPharma, Inc. on Form 13F. Percentages are the stock's share of each portfolio.
HHLR Advisors (Hillhouse)
Zhang Lei
16.4%
ArriVent BioPharma, Inc.'s share of the portfolio
- Shares
- 3,929,117
- Value
- $136.5M
Latest insider trades
Open-market purchases and sales by ArriVent BioPharma, Inc. insiders from Form 4, newest first.
| Filed (ET) | Trade date | Filing delay | Insider | Transaction | Shares | Avg price | Value | Holding change | Flags |
|---|---|---|---|---|---|---|---|---|---|
| Feb 3, 2026 (view filing)4:05 PM ET | Dec 10, 2025 | 55 daysLate | Hillhouse Investment Management, Ltd. and 1 other10% Owner | SSale | −555.6K | $23.37 | −$13.0M | −12.4%3.93M after | |
| Feb 1, 2024 (view filing)4:47 PM ET | Jan 30 | 2 days | Hillhouse Investment Management, Ltd. and 1 other10% Owner | PPurchase | +555.6K | $18.00 | +$10.0M | +14.1%4.48M after | |
| Jan 31, 2024 (view filing)4:12 PM ET | Jan 30 | 1 day | OrbiMed Advisors LLC and 3 othersDirector, 10% Owner | PPurchase | +444.4K | $18.00 | +$8.00M | +41.6%1.51M after | 2 lotsDuplicate filing |
| Jan 31, 2024 (view filing) | Jan 30 | 1 day | Gordon Carl LDirector, 10% Owner | PPurchase | +444.4K | $18.00 | +$8.00M | +41.6%1.51M after | 2 lots |
| Jan 31, 2024 (view filing) | Jan 30 | 1 day | Healy JamesDirector | PPurchase | +444.4K | $18.00 | +$8.00M | +35.5%1.70M after |
Top 10 13F holders, Q2 2026
The largest institutional positions in ArriVent BioPharma, Inc. at the end of Q2 2026; share changes are against Q1 2026.
| Institution | Shares | Value | % of portfolio | Change in shares | Action |
|---|---|---|---|---|---|
| Suvretta Capital Management, LLC | 4,515,531 | $156.9M | 3.30% | +114,448+2.6% | Added |
| Infinitum Asset Management, LLC | 4,438,384 | $154.2M | 15.68% | +289,461+7.0% | Added |
| HHLR Advisors, Ltd.SuperinvestorHHLR Advisors (Hillhouse) | 3,929,117 | $136.5M | 16.40% | 00.0% | Unchanged |
| BlackRock, Inc. | 3,250,396 | $112.9M | 0.00% | +720,095+28.5% | Added |
| OrbiMed Advisors LLC | 3,027,328 | $105.2M | 1.99% | 00.0% | Unchanged |
| FMR LLC | 2,778,959 | $96.5M | 0.00% | −237,173−7.9% | Reduced |
| Octagon Capital Advisors LP | 1,971,054 | $68.5M | 6.28% | 00.0% | Unchanged |
| Vanguard Capital Management LLC | 1,774,873 | $61.7M | 0.00% | +245,980+16.1% | Added |
| Sofinnova Investments, Inc. | 1,696,752 | $58.9M | 3.15% | 00.0% | Unchanged |
| State Street Corp | 1,692,986 | $58.8M | 0.00% | +271,571+19.1% | Added |